Hologic INC Form 4 insider transactions

Hologic, Inc. has completed its merger, resulting in significant changes to executive beneficial ownership of company securities.

Brandon Schnittker reports on changes in beneficial ownership of Hologic Inc. following a merger, detailing the conversion of stock options and units into cash and contingent value rights.

Jennifer M. Schneiders reports on changes in beneficial ownership following Hologic Inc.'s merger, with stock options and performance units converted to cash and contingent value rights.

Hologic Inc. Chief Financial Officer Karleen Marie Oberton reports on changes in beneficial ownership following the company's merger.

Hologic's Chief Operating Officer, Mitchell Essex, filed a Form 4 detailing transactions related to the company's merger, including the conversion of stock options and performance units into merger consideration.

Hologic Inc. has completed its merger, resulting in changes to executive beneficial ownership and the conversion of stock options and units into cash and contingent value rights.

Mark W. Horvath, President of Breast & Skeletal at Hologic Inc., reported changes in beneficial ownership following the company's merger.

Hologic, Inc. has completed its merger, with reporting person Diana De Walt no longer beneficially owning common stock following the transaction.

Hologic, Inc. announces the completion of its merger, resulting in changes to insider beneficial ownership and the conversion of stock options and RSUs.

Hologic Inc. reports the completion of its merger, resulting in the cancellation of executive stock options and changes in beneficial ownership.

Hologic Inc. announces the completion of its merger, resulting in changes to executive beneficial ownership of company securities.

Hologic Inc. has completed its merger, with reporting person Nanaz Mohtashami no longer beneficially owning direct or indirect shares following the transaction.

Hologic, Inc. has completed its merger, resulting in changes to executive beneficial ownership of common stock and stock options.

Hologic, Inc. announces the completion of its merger with Hopper Parent Inc., resulting in significant changes to executive beneficial ownership and stock option holdings.

Stephen P. MacMillan, Chairman, President and CEO of Hologic Inc., reports changes in beneficial ownership following the company's merger, with all common stock and options converted to cash and contingent value rights.

Ludwig Hantson, a Director at Hologic Inc., reported transactions involving common stock and stock options on April 7, 2026, following a merger.

Hologic Inc. announces the completion of its merger, leading to significant changes in beneficial ownership for reporting persons.

Hologic Inc. insider Benjamin Jordan Cohn reports on transactions related to the company's merger, including the conversion of stock options and performance units.

Hologic Inc. Director Amy Wendell reported the acquisition of 3,190 restricted stock units, increasing her direct beneficial ownership to 25,784 shares.

Hologic Inc. Director Stacey D. Stewart reported the acquisition of 3,190 restricted stock units, increasing her beneficial ownership.

Hologic Inc. Director Christiana Stamoulis reported the acquisition of 3,190 restricted stock units, increasing her beneficial ownership.

Hologic Inc. Director Nanaz Mohtashami acquired 3,190 restricted stock units, increasing her beneficial ownership to 7,371 units.

Hologic Inc. Director Wayde D. McMillan reported the acquisition of 3,190 restricted stock units, increasing his beneficial ownership.

Hologic Inc. Director Martin D. Madaus acquired 3,190 restricted stock units, vesting at the 2027 Annual Meeting of Stockholders.

Hologic Inc. Director Ludwig Hantson reported the acquisition of 3,190 restricted stock units, increasing his beneficial ownership.

Hologic Inc. Director Charles J. Dockendorff acquired 3,190 restricted stock units, aligning his interests with shareholders.

Hologic's President of Breast & Skeletal, Mark W. Horvath, disposed of 113 common shares to cover tax obligations related to vested restricted stock units.

Hologic's SVP of Human Resources, Diana De Walt, filed an amended Form 4 to correct an administrative error regarding her Power of Attorney, with no changes to previously reported stock transactions.

Hologic's SVP of Human Resources, Diana De Walt, disposed of 4,416 shares of common stock at $74.93 per share to cover tax obligations related to restricted stock unit vesting.

Hologic's President of GYN Surgical, Brandon Schnittker, reported a tax-related disposition of 90 common shares at $75 per share.